公开(公告)号：US09352039B2

公开(公告)日：2016-05-31

申请号：US14376923

申请日：2013-02-08

Applicant: The Regents of the University of Michigan

Inventor： Suling Liu ,  Max S. Wicha

IPC: A61K39/395 ,  A61K31/7088 ,  C12N15/113 ,  A61K45/06 ,  A61K39/00 ,  G01N33/574

CPC classification number: A61K39/3955 ,  A61K31/7088 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/507 ,  A61K2039/5154 ,  C12N15/1135 ,  C12N15/1136 ,  C12N15/1138 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2320/31 ,  C12N2330/50 ,  G01N33/57484 ,  A61K2300/00

Abstract: Compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states are disclosed. In some methods, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain methods, the different states of cancer stem cells are distinguished based on markers CD44+CD24−, EpCam−CD49P+ (for EMT cancers stem cells), ALDH+ and EPCam+CD49r− (for MET cancers stem cells), and CD44+CD24−ALDH+ (for EMT-MET cancer stem cells). In particular methods, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).

Abstract translation: 基于识别或使用不同状态的癌症干细胞（包括EMT中的癌症干细胞（上皮至间质转换）MET（间质至上皮转换））的治疗筛选，诊断和癌症治疗的组合物，试剂盒和方法 ，并且公开了EMT-MET状态。 在一些方法中，使用靶向EMT癌症干细胞的一种治疗剂和靶向MET癌症干细胞的第二种治疗剂治疗受试者。 在某些方法中，基于标记物CD44 + CD24-，EpCam-CD49P +（用于EMT癌症干细胞），ALDH +和EPCam + CD49r-（对于MET癌症干细胞）和CD44 + CD24来区分不同状态的癌症干细胞 -ALDH +（用于EMT-MET癌症干细胞）。 在特定方法中，微RNA用于转变成特定的癌症干细胞类型（例如，用于EMT的mir-100和用于MET的mir-93）。

公开(公告)号：US20150125469A1

公开(公告)日：2015-05-07

申请号：US14376923

申请日：2013-02-08

Applicant: The Regents of the University of Michigan

Inventor： Suling Liu ,  Max S. Wicha

IPC: A61K39/395 ,  A61K39/00 ,  G01N33/574

CPC classification number: A61K39/3955 ,  A61K31/7088 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/507 ,  A61K2039/5154 ,  C12N15/1135 ,  C12N15/1136 ,  C12N15/1138 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2320/31 ,  C12N2330/50 ,  G01N33/57484 ,  A61K2300/00

Abstract: Compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states are disclosed. In some methods, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain methods, the different states of cancer stem cells are distinguished based on markers CD44+CD24−, EpCam−CD49P+(for EMT cancers stem cells), ALDH+ and EPCam+CD49r− (for MET cancers stem cells), and CD44+CD24−ALDH+ (for EMT-MET cancer stem cells). In particular methods, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).

Abstract translation: 基于识别或使用不同状态的癌症干细胞（包括EMT中的癌症干细胞（上皮至间质转换）MET（间质至上皮转换））的治疗筛选，诊断和癌症治疗的组合物，试剂盒和方法 ，并且公开了EMT-MET状态。 在一些方法中，使用靶向EMT癌症干细胞的一种治疗剂和靶向MET癌症干细胞的第二种治疗剂治疗受试者。 在某些方法中，基于标记物CD44 + CD24-，EpCam-CD49P +（用于EMT癌症干细胞），ALDH +和EPCam + CD49r-（对于MET癌症干细胞）和CD44 + CD24来区分不同状态的癌症干细胞 -ALDH +（用于EMT-MET癌症干细胞）。 在特定方法中，微RNA用于转变成特定的癌症干细胞类型（例如，用于EMT的mir-100和用于MET的mir-93）。